Anti-B7H3 ADC
|
Oncology/Cancer
|
Broad cancer
|
PCC
|
Global
| |
Best-in-class IRAK4 Degrader
|
Immunological disease
|
Psoriasis,RA,Inflammatory bowel disease (IBD),autoimmune inflammatory diseases
|
PCC
|
Global
| |
Best-in-class IRAK4 Degrader
|
Immunological disease
|
Psoriasis,RA,Inflammatory bowel disease (IBD),or other autoimmune inflammatory diseases
|
PCC
|
Global
| |
See in our "Antibody Licensing" platform
|
|
Next to "Licensing" Tab in the top
|
PCC
|
| |
B7H3/PD-L1 bsAb
|
Oncology/Cancer
|
Advanced solid tumor
|
Preclinical
|
Global
| |
CCR8 mAb (sequence cooperation)
|
Oncology/Cancer
|
Solid Tumor
|
Preclinical
|
Global
| |
FRa BsAb (sequence cooperation)
|
Oncology/Cancer
|
Ovarian cancer
|
Preclinical
|
Global
| |
GCC mAb (sequence cooperation)
|
Oncology/Cancer
|
Solid Tumor
|
Preclinical
|
Global
| |
GLP-1/GIP/FGF21 fusion protein
|
Metabolic disease
|
NASH,Type 2 diabetes,hyperlipidemia
|
Preclinical
|
Global (except China)
| |
GPCR selective agonist
|
Immunological disease
|
Duchenne muscular dystrophy,SLE
|
Preclinical
|
Global
| |
B7H3+CD3 BsAb
|
Oncology/Cancer
|
Solid Tumor
|
IND
|
Global
| |
CD47 mAb
|
Oncology/Cancer
|
Advanced solid tumor,Advanced hematological tumor
|
IND
|
Global
| |
CLDN 18.2 CAR-T
|
Oncology/Cancer
|
Gastric Cancer,Pancreatic Cancer
|
IND
|
Global
| |
GLP-1/GIP/GCG fusion protein
|
Metabolic disease
|
T2DM,Obesity
|
IND
|
Global
| |
Small Molecule Drug for Cardiac Hypertrophy and Fibrosis against Heart Failure
|
Cardiovascular
|
Cardiac hypertrophy and Fibrosis against Heart Failure
|
IND
|
Global
| |